PLx Pharma Inc (NASDAQ:PLXP) insider Michael J. Valentino acquired 44,404 shares of the stock in a transaction that occurred on Monday, May 20th. The stock was purchased at an average price of $5.60 per share, with a total value of $248,662.40. The purchase was disclosed in a filing with the SEC, which is accessible through this link.
PLx Pharma stock opened at $5.00 on Thursday. PLx Pharma Inc has a one year low of $1.00 and a one year high of $6.44. The company has a debt-to-equity ratio of 0.66, a current ratio of 4.86 and a quick ratio of 4.86. The stock has a market cap of $43.77 million, a PE ratio of -3.70 and a beta of 5.01.
PLx Pharma (NASDAQ:PLXP) last issued its earnings results on Friday, May 10th. The biotechnology company reported ($0.36) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.33) by ($0.03). The firm had revenue of $0.32 million during the quarter, compared to the consensus estimate of $0.30 million. PLx Pharma had a negative net margin of 1,507.67% and a positive return on equity of 31.28%. On average, sell-side analysts expect that PLx Pharma Inc will post -1.28 earnings per share for the current fiscal year.
A number of analysts recently commented on the stock. Zacks Investment Research upgraded shares of PLx Pharma from a “sell” rating to a “hold” rating in a research report on Wednesday. JMP Securities started coverage on shares of PLx Pharma in a research report on Thursday, March 14th. They issued an “outperform” rating for the company. Janney Montgomery Scott started coverage on shares of PLx Pharma in a research note on Friday, April 12th. They issued a “buy” rating for the company. Finally, ValuEngine raised shares of PLx Pharma from a “sell” rating to a “hold” rating in a research note on Friday, February 15th. Three analysts have rated the stock with a hold rating and two have given a buy rating to the stock. PLx Pharma has an average rating of “Hold”.
Several hedge funds and other institutional investors have recently bought and sold shares of PLXP. Northern Trust Corp acquired a new stake in shares of PLx Pharma during the 1st quarter worth approximately $59,000. Renaissance Technologies LLC boosted its position in shares of PLx Pharma by 34.1% during the 1st quarter. Renaissance Technologies LLC now owns 58,612 shares of the biotechnology company’s stock worth $308,000 after acquiring an additional 14,900 shares in the last quarter. Vanguard Group Inc. boosted its position in shares of PLx Pharma by 98.0% during the 3rd quarter. Vanguard Group Inc. now owns 163,431 shares of the biotechnology company’s stock worth $662,000 after acquiring an additional 80,910 shares in the last quarter. Vanguard Group Inc boosted its position in shares of PLx Pharma by 98.0% during the 3rd quarter. Vanguard Group Inc now owns 163,431 shares of the biotechnology company’s stock worth $662,000 after acquiring an additional 80,910 shares in the last quarter. Finally, Park West Asset Management LLC boosted its position in shares of PLx Pharma by 37.0% during the 4th quarter. Park West Asset Management LLC now owns 1,473,218 shares of the biotechnology company’s stock worth $2,254,000 after acquiring an additional 397,495 shares in the last quarter. Institutional investors and hedge funds own 24.37% of the company’s stock.
About PLx Pharma
PLx Pharma Inc, a late-stage specialty pharmaceutical company, focuses on developing its PLxGuard delivery system to provide various products in the United States. The company's lead product candidates are Vazalore 325 mg and Vazalore 81 mg, which are formulations of aspirin that use the PLxGuard delivery system to reduce acute gastrointestinal (GI) side effects while providing antiplatelet effectiveness for cardiovascular disease prevention.
Further Reading: Sell-Side Analysts
Receive News & Ratings for PLx Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PLx Pharma and related companies with MarketBeat.com's FREE daily email newsletter.